European Commission approves Amgen's new cholesterol-lowering medication Repatha™ (evolocumab)
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced that the European Commission (EC) has granted marketing authorization for Repatha™ (evolocumab), the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol (LDL-C) reduction.
AstraZeneca completes agreement with Tillotts Pharma for Entocort
- Details
- Category: AstraZeneca
AstraZeneca has completed its agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort ® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease and ulcerative colitis.
Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients
- Details
- Category: Novartis
Novartis antimalarial medicine Coartem® 80/480mg has received World Health Organization (WHO) prequalification, making it the first and only high strength (80/480mg) Artemisinin-based Combination Therapy (ACT) antimalarial treatment available for public sector procurement.
IRESSA approved by US FDA for first-line treatment of patients with advanced EGFR mutation-positive non-small cell lung cancer
- Details
- Category: AstraZeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved IRESSA (gefitinib) tablets, 250mg once daily, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.
Pfizer's Centers for Therapeutic Innovation and Jeffrey Modell Foundation announce collaboration
- Details
- Category: Pfizer
Pfizer's Centers for Therapeutic Innovation (CTI) and the Jeffrey Modell Foundation (JMF) announced a collaboration agreement to conduct research in the field of immunological diseases. CTI and JMF will identify and co-fund translational research projects with leading academic medical centers within the CTI network.
AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma
- Details
- Category: AstraZeneca
AstraZeneca announced today that it has entered into an agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease and ulcerative colitis.
Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches
- Details
- Category: Novartis
Novartis Pharmaceuticals announced the release of new features for its ViaOpta applications, and the extension for use with smart watches. The discreet, hands-free nature of using ViaOpta app with wearable devices, such as Apple Watch and Android Wear, provides users with an experience that seamlessly fits into their existing routines allowing those with visual impairments to navigate daily life with even greater ease.
More Pharma News ...
- Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.
- Pfizer enters into agreement to acquire Nimenrix and Mencevax from GlaxoSmithKline
- Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
- Roche employees unite to raise funds for children in need
- Bayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million
- Patients reporting better quality of communication by their physician show improved self-care
- Get Ready. Get Set. Get Old.